



Achieving high seroprevalence against polioviruses in Sri Lanka-Results from a serological survey, 2014

Deepa Gamage^a, Paba Palihawadana^a, Ondrej Mach^{b,*},
William C. Weldon^c, Steven M. Oberste^c, Roland W. Sutter^b

^a *Epidemiology Unit, Ministry of Health, Sri Lanka*

^b *Polio Eradication Department, World Health Organization, Geneva, Switzerland*

^c *Polio and Picornavirus Laboratory Branch, Centers for Disease Control and Prevention, Atlanta, GA, USA*

Received 28 January 2015; received in revised form 2 June 2015; accepted 3 June 2015
Available online 9 July 2015

KEYWORDS

Immunization;
Poliomyelitis;
Seroprevalence; Sri Lanka

Abstract The immunization program in Sri Lanka consistently reaches >90% coverage with oral poliovirus vaccines (OPV), and no polio supplementary vaccination campaigns have been conducted since 2003. We evaluated serological protection against polioviruses in children. A cross-sectional community-based survey was performed in three districts of Sri Lanka (Colombo, Badulla, and Killinochi). Randomly selected children in four age groups (9–11 months, 3–4 years, 7–9 years, and 15 years) were tested for poliovirus neutralizing antibodies. All 400 enrolled children completed the study. The proportion of seropositive children for poliovirus Type 1 and Type 2 was >95% for all age groups; for poliovirus Type 3 it was 95%, 90%, 77%, and 75% in the respective age groups. The vaccination coverage in our sample based on vaccination cards or parental recall was >90% in all age groups. Most Sri Lankan children are serologically protected against polioviruses through routine immunization only. This seroprevalence survey provided baseline data prior to the anticipated addition of inactivated poliovirus vaccine (IPV) into the Sri Lankan immunization program and the switch from trivalent OPV (tOPV) to bivalent OPV (bOPV). © 2015 Ministry of Health, Saudi Arabia. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1. Introduction

With polio eradication making rapid progress, only three countries remain in 2014 which had never eradicated wild poliovirus (Afghanistan, Nigeria,

* Corresponding author at: Research and Product Development Team, Global Polio Eradication Initiative, World Health Organization, Avenue Appia 20, CH-1211 Genève 27, Switzerland.
E-mail address: macho@who.int (O. Mach).

and Pakistan) [1]. In this context, a high priority is assigned to the preparations for the posteradication era. The key policy changes described in the Polio Eradication and Endgame Strategic Plan 2013–2018 [2] are global cessation of the Type 2 component of the oral poliovirus vaccine (OPV) (meaning the switch from trivalent OPV [tOPV] to bivalent OPV [bOPV]); and the global introduction of at least one dose of inactivated poliovirus vaccine (IPV) into every country's routine immunization schedule. The strategy will allow for cessation of circulation and emergence of vaccine-derived poliovirus Type 2 (VDPV 2) while the last endemic foci of wild poliovirus are cleared [3].

The last case of poliomyelitis in Sri Lanka was reported in 1993 [4]. The routine immunization program in Sri Lanka is considered to be performing well and includes five doses of OPV administered at 2, 4, and 6 months of age as a primary series followed by revaccinations at 18 months and 5 years of age. The vaccination coverage with the third OPV dose has consistently exceeded 95% nationwide [5]. Supplementary immunization activities have been conducted to address known population immunity gaps from 1995 to 2003, and there has been no polio vaccination campaign since 2003.

Sri Lanka plans to introduce one dose of IPV into its routine immunization schedule in 2015. Following the recommendation of the Strategic Advisory Group of Experts, one dose of IPV will be introduced into the routine immunization schedule of all OPV-using countries in 2015; this IPV dose will be co-administered with a dose of OPV after 14 weeks of age [6]. The switch from tOPV to bOPV is planned for April 2016.

This study provides baseline data on seroprevalence of polio neutralizing antibodies in targeted age groups in Sri Lanka in anticipation of the IPV introduction and tOPV to bOPV switch.

2. Methods

We performed a cross-sectional community-based survey in three districts of Sri Lanka: Colombo, Badulla, and Killinochi. The study area purposefully represented the lower socioeconomic strata of the Sri Lankan society: in Colombo, children were selected from urban slum areas; in Badulla children of tea plantation workers were selected; and the district of Killinochi is considered less developed overall. Children in four age groups were selected: 9–11 months, 3–4 years, 7–9 years, and 15 years of age. The age groups were selected to assess serological protection achieved after primary immunization series as well as after revaccinations

with OPV at 18 months and 5 years. The oldest age group was selected to assess serological protection in older children.

The participants were selected using simple random sampling from field level health registers kept with the Medical Officers of Health. Parents of eligible children were approached during regular visits of Public Health Midwives, consented, and enrolled. On the same day, the participants were transported to the nearest health center where a 1 mL blood sample was collected and a short questionnaire administered.

The blood specimens were allowed to clot. Sera were separated and transported to Colombo, where they were stored at -20°C until the shipment to the Centers for Disease Control and Prevention (CDC) in Atlanta, GA, USA. The sera were tested for the presence of poliovirus neutralizing antibodies using standard neutralization assays at the virological laboratory at the CDC [7,8]. Seropositivity was defined as reciprocal titers of poliovirus neutralizing antibodies ≥ 8 .

The vaccination history of the enrolled children was recorded from vaccination cards when available; otherwise the history was obtained through parental recall.

A sample size of 100 children in each age group (to a total of 400 children) was calculated to be sufficient to detect, at the 95% confidence level, a seroprevalence point estimate with a precision of approximately $\pm 5\%$ assuming $\geq 90\%$ seroprevalence.

Ethical clearance was obtained by the Ethical Committees of the Ministry of Health, Sri Lanka and of the World Health Organization, Geneva, Switzerland.

Statistical analysis was performed using EpiInfo 3.5.3., point estimates and 95% confidence intervals were calculated for seroprevalence proportions and for median titers. The Chi-square uncorrected two-tailed p value was calculated to assess statistically significant differences in baseline characteristics between districts; we considered any $p < 0.05$ as an indicator of statistical significance.

This study was approved by the Ethics Review Committee of the Ministry of Health, Sri Lanka and by the WHO's Ethics Review Committee in Geneva.

3. Results

We enrolled 400 eligible children and 400/400 (100%) completed the study. We did not encounter any dropout because enrollment and the blood

Download English Version:

<https://daneshyari.com/en/article/3327533>

Download Persian Version:

<https://daneshyari.com/article/3327533>

[Daneshyari.com](https://daneshyari.com)